Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device
Launched by AESCULAP AG · Jul 11, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients who received a Arcadius XP L® interbody fusion device between 2016 until approx. January 2021 (minimum Follow-up is one year) in the study center
- • all indications as given by the instructions for use: degenerative disc disease (DDD), Instability, Spondylolisthesis up to grade 1, Post-discectomy syndrome, Post-traumatic instability
- • Written informed consent for the documentation of clinical and radiological results
- Exclusion Criteria:
- • Patient is not willing or able to participate at the follow-up examination
- • Patients living outside a radius of 100 km around the study center
- * all contraindications as given by the instructions for use:
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nürtingen, Baden Württemberg, Germany
Nürtingen, , Germany
Esslingen, Baden Württemberg, Germany
Schorndorf, Baden Württemberg, Germany
Esslingen, , Germany
Schorndorf, , Germany
Patients applied
Trial Officials
Wolfram Reithmeier, Dr.
Principal Investigator
Schelztor-Klinik
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported